Browse by author
Lookup NU author(s): Professor Nicola CurtinORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Most established cancer therapy regimes involve DNA-damaging chemotherapy or radiotherapy. The DNA repair capacity of the tumour, therefore, represents a mechanism of therapeutic resistance. Drugs to inhibit DNA repair pathways have been developed and they demonstrate good chemosensitisation and radiosensitisation activity in preclinical models. Two classes of DNA repair inhibitors have entered clinical trial and show promising activity. Genetic instability in tumours may be at least partially due to defects in DNA repair pathways, such defects may underlie the inherent sensitivity of some tumours to certain classes of anticancer agent. DNA repair defects may also make the tumour dependent on complimentary or back-up pathways; laboratory evidence shows that targeting these complimentary pathways results in tumour-selective therapy. © 2007 Informa UK Ltd.
Author(s): Curtin NJ
Publication type: Review
Publication status: Published
Journal: Expert Opinion on Therapeutic Targets
Print publication date: 01/06/2007
ISSN (print): 1472-8222
ISSN (electronic): 1744-7631
PubMed id: 17504016